The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The feasibility of tumor-infiltrating lymphocyte expansion in non-clear cell renal cell carcinoma.
 
Christopher Guske
No Relationships to Disclose
 
Marine Potez
No Relationships to Disclose
 
Justin Miller
No Relationships to Disclose
 
Jeffrey Johnson
No Relationships to Disclose
 
Johannes Ali
No Relationships to Disclose
 
Michael Carter
No Relationships to Disclose
 
Fatema Khambati
No Relationships to Disclose
 
Adnan Fazili
No Relationships to Disclose
 
Keerthi Gullapalli
No Relationships to Disclose
 
Wade Sexton
Consulting or Advisory Role - pacific edge; Urogen pharma
 
Logan Zemp
No Relationships to Disclose
 
Brandon Manley
Consulting or Advisory Role - Merck; Merck
Patents, Royalties, Other Intellectual Property - EGFR splice variant as a biomarker in renal cancer (Inst)
Expert Testimony - Arnold & Porter
 
Gabriel Roman Souza
No Relationships to Disclose
 
Matthew Beatty
Consulting or Advisory Role - TuHura Biosciences
Research Funding - Turnstone Bio (Inst)
 
Philippe Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN; President of Global Society of Rare GU Tumors; Société Internationale d’Urologie Journal
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Shari Pilon-Thomas
Consulting or Advisory Role - KSQ Therapeutics; Morphogenesis, Inc.
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Dyve Biosciences (Inst); Intellia Therapeutics (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - IP licensed from Moffitt to Tuhura. (Inst); Moffitt Cancer Center has licensed Intellectual Property related to the proliferation and expansion of tumor infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Shari Pilon-Thomas is an inventor on such Intellectual Property. (Inst); Patent with Provectus (Inst)
 
Jad Chahoud
Consulting or Advisory Role - AVEO; DAVA Pharmaceuticals; Eisai; Exelixis; Merck; Pfizer